scholarly journals A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

2018 ◽  
Vol 7 (1) ◽  
Author(s):  
Henrik Gregersen ◽  
Trung Do ◽  
Ida Bruun Kristensen ◽  
Ulf Christian Frølund ◽  
Niels Frost Andersen ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Study ◽  
High Dose ◽  
Newly Diagnosed ◽  
Stem Cell Support ◽  
High Dose Melphalan ◽  
Cell Support

A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3073-3073
Author(s):  
Peter Gimsing ◽  
Oyvind Hjertner ◽  
Niels Abildgaard ◽  
Niels Frost Andersen ◽  
Tobias Gedde Dahl ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Induction Therapy ◽  
Response Rate ◽  
Phase Ii Study ◽  
High Dose ◽  
Stem Cell Support ◽  
First Relapse ◽  
High Dose Melphalan ◽  
Cell Support

Abstract Abstract 3073 Introduction. The prognosis of multiple myeloma has improved significantly during the last three decades especially in the younger patient who are eligible for high-dose chemotherapy with autologous stem cell support (ASCT). However, in spite of prolonged progression free survival (PFS) the patients will eventually experience treatment demanding relapse. As many of the patients still have stored frozen stem cells, it is a widespread routine to offer another ASCT after re-induction therapy or in some cases directly without induction therapy. Only few reports of the results of ASCT in the relapse setting have been published and all have been retrospective analyses. It is well known that the time from first ASCT to relapse has an impact on both PFS and on overall survival (OS) after second-line treatment (Alegre et al, 2002, Alvares et al, 2005, Lenhoff et al, 2006). New drugs like bortezomib and lenalidomide have improved the PFS and OS at relapse also in some of the bad-risk patients. Therefore, we decided to determine the effect of induction therapy with bortezomib and dexamethasone and including bortezomib in the conditioning regimen with high-dose melphalan (HDM) in the relapse setting, which has also been addressed by the French group (Roussel et al, 2011). Inclusion criteria. Patients formerly treated for multiple myeloma with HDM with stem cell support as first line treatment and who had first symptomatic relapse and had stored more than 2.0 × 106 CD34+ stem cell/ kg body weight. Exclusion criteria. Former treatment with bortezomib. Study design. Prospective non-randomised phase II study. Study treatment. Three courses of bortezomib 1.3 mg/m2 (Velcade®) days 1, 4, 8 and 11 and dexamethasone 20 mg days 1, 2, 4, 5, 8, 9, 11 and 12 (btz-dex) followed by Melphalan (200 mg/m2) on day –2 with bortezomib 1.3 mg/m2 days –5 and –2, and reinfusion of more than 2.0 × 106 CD34+ stem cells/kg body weight on day 0. Prophylactic treatment for herpes zoster was giving according to local routine. Primary end-point: Comparison of PFS after the first ASCT and the second ASCT with bortezomib included in induction and conditioning at first relapse. Secondary end-points: Toxicity of bortezomib as part of the high-dose melphalan conditioning, response rate of the second ASCT and comparison of time schedule for marrow regeneration (neutrophil- and platelet recovery) in the first and second ASCT. Pre-planned exploratory subgroup analysis of patients with early relapse (within first year) vs. later relapse, different types of relapse. Results. 53 patients relapsing from 3.5 to 112.3 months after initial ASCT (7 patients had received initial tandem ASCT) were included. Four included patients never went forward to ASCT after relapse: one patient died from septicemia shortly after one bortezomib injection, one patient developed respiratory insufficiency after the second btz-dex course and two patients had aggressive progression after the third btz-dex course. The table summarises the results of the 49 patients who completed the ASCT after first relapse. The ratios between the second and first PFS (Hermansen & Gimsing, 2008) were calculated and showed median: 0.9 (range: 0 – 1.77). Detailed safety data will be presented. Conclusion: Salvage high-dose melphalan with bortezomib and stem cell support after reinduction with btz-dex at first relapse after high-dose therapy with saved frozen stem cells is a safe treatment with high response rate and reasonable long PFS compared to the initial treatment. Disclosures: No relevant conflicts of interest to declare.

scholarly journals High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study

2001 ◽  
Vol 85 (9) ◽  
pp. 1240-1246 ◽  
Author(s):  
P H Cottu ◽  
J M Extra ◽  
M Espie ◽  
J P Marolleau ◽  
A de Roquancourt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Advanced Breast Cancer ◽  
Phase Ii ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Phase Ii Study ◽  
High Dose ◽  
Stem Cell Support ◽  
Cell Support

Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma

2001 ◽  
Vol 66 (5) ◽  
pp. 328-336 ◽  
Author(s):  
Nina Gulbrandsen ◽  
Finn Wisløff ◽  
Erik Nord ◽  
Stig Lenhoff ◽  
Martin Hjorth ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Autologous Blood ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
High Dose ◽  
Utility Analysis ◽  
Stem Cell Support ◽  
High Dose Melphalan ◽  
Cell Support

High-Dose Melphalan, Etoposide, Total-Body Irradiation, and Autologous Stem-Cell Reconstitution as Consolidation Therapy for High-Risk Ewing’s Sarcoma Does Not Improve Prognosis

2001 ◽  
Vol 19 (11) ◽  
pp. 2812-2820 ◽  
Author(s):  
Paul A. Meyers ◽  
Mark D. Krailo ◽  
Marc Ladanyi ◽  
Ka-Wah Chan ◽  
Scott L. Sailer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Progressive Disease ◽  
Peripheral Blood Stem Cell ◽  
High Dose ◽  
Consolidation Therapy ◽  
Newly Diagnosed ◽  
Stem Cell Support ◽  
Total Body ◽  
High Dose Melphalan ◽  
Cell Support

PURPOSE: To determine whether consolidation therapy with high-dose melphalan, etoposide, and total-body irradiation (TBI) with autologous stem-cell support would improve the prognosis for patients with newly diagnosed metastatic Ewing’s sarcoma (ES). PATIENTS AND METHODS: Thirty-two eligible patients with newly diagnosed ES metastatic to bone and/or bone marrow were enrolled onto this study. Treatment was initially comprised of five cycles of induction chemotherapy (cyclophosphamide, doxorubicin, and vincristine alternating with ifosfamide and etoposide) and local control. Peripheral-blood stem-cell collection was performed after the second cycle of chemotherapy, with delay if the bone marrow was persistently involved. If patients had a good response to initial therapy, they proceeded to consolidation therapy with melphalan, etoposide, TBI, and stem-cell support. RESULTS: Of the 32 eligible patients, 23 proceeded to high-dose therapy consolidation. Of the nine patients who did not proceed to consolidation, four were secondary to progressive disease and two were secondary to toxicity. Three patients died from toxicity during the high-dose phase of the therapy. The majority of the patients who underwent high-dose consolidation therapy experienced relapse and died with progressive disease. Two-year event-free survival (EFS) for all eligible patients is 20%. The 2-year post–stem-cell reconstitution EFS for the subset of 23 patients who received consolidation therapy is 24%. Analysis of peripheral-blood stem-cell collections by molecular techniques for minimal residual disease showed contamination of at least some samples by tumor cells in all three patients with available data. CONCLUSION: Consolidation with high-dose melphalan, etoposide, TBI, and autologous stem-cell support failed to improve the probability of EFS in this cohort of patients with newly diagnosed metastatic ES.

scholarly journals miRNAs as Indices Predicting Early Toxicity in High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Support in Multiple Myeloma Patients

2018 ◽  
Vol 18 ◽  
pp. S244
Author(s):  
Agnieszka Szeremet ◽  
Tomasz Wrobel ◽  
Mateusz Olbromski ◽  
Natalia Glatzel-Plucinska
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
High Dose ◽  
Stem Cell Support ◽  
High Dose Melphalan ◽  
Early Toxicity ◽  
Cell Support

scholarly journals A Phase II study of153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

2010 ◽  
pp. NA-NA
Author(s):  
Angela Dispenzieri ◽  
Gregory A. Wiseman ◽  
Martha Q. Lacy ◽  
Suzanne R. Hayman ◽  
Shaji K. Kumar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Phase Ii ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Phase Ii Study ◽  
Conditioning Regimen ◽  
Blood Stem Cell ◽  
High Dose ◽  
High Dose Melphalan

Favorable prognostic impact ofRASmutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective

2015 ◽  
Vol 57 (1) ◽  
pp. 226-229 ◽  
Author(s):  
Niklas Gebauer ◽  
Harald Biersack ◽  
Ann-Cathrin Czerwinska ◽  
Janina Schemme ◽  
Tim Tristan Hardel ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Novel Agents ◽  
High Dose ◽  
Prognostic Impact ◽  
Single Center ◽  
Stem Cell Support ◽  
High Dose Melphalan ◽  
Cell Support

Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study

2014 ◽  
Vol 22 (11) ◽  
pp. 2911-2916 ◽  
Author(s):  
Thomas Bechtel ◽  
Ali McBride ◽  
Brooke Crawford ◽  
Susan Bullington ◽  
Craig C. Hofmeister ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Phase Ii ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Phase Ii Study ◽  
High Dose ◽  
Delayed Nausea ◽  
Cell Transplants ◽  
High Dose Melphalan
Sign in / Sign up

Export Citation Format

Share Document